Teva Pharmaceutical's $450 million settlement highlights the challenges of compliance in the pharmaceutical industry. The Department of Justice accused Teva of violating the anti-kickback statute and the False Claims Act by using co-payment assistance programs to steer Medicare payments for its drug Copaxone while raising prices. Additionally, Teva admitted to price-fixing schemes for generic drugs like pravastatin. This case serves as a stark reminder that compliance isn't just about avoiding penalties—it's about building trust with patients, healthcare providers, and regulators.

The key question for companies is: how robust is your compliance program? Are you ready for federal and state scrutiny? If you’re navigating these complexities, the Kulkarni Law Firm is here to help ensure your operations remain compliant and ethical. Reach out before small issues turn into costly legal battles.

Support the show